Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to biosimilar developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s very successful biologic Humira (adalimumab). Biosimilars of Humira have been available in Europe since October 2018. Biosimilars referencing Roche’s Rituxan / MabThera (rituximab) have also launched in Europe and the United States. As the immune biosimilar space becomes increasingly competitive, it is important that manufacturers and marketers of biosimilars and branded biologics understand the factors that most influence physicians’ choice of therapy. Based on primary market research conducted by Clarivate in the United States, France, and Germany with physicians from two specialties (gastroenterology and rheumatology), clients will gain a clear overview of physicians’ experiences with and attitudes toward biosimilars and understand these drugs’ evolution over the last three years (2020, 2021, and 2022).
Understand current biosimilar use. What are the current levels of experience prescribing biosimilars across different specialties? How do physicians perceive currently available biosimilars?
Understand the drivers, barriers, and physicians’ attitudes regarding biosimilar uptake. What are the greatest drivers of/barriers to biosimilar use? How familiar with biosimilars are physicians across different specialties? How similar do physicians perceive biosimilars and reference brands to be? Are physicians aware of the pharmacy-level substitution rules in their own country, and would they expect to prevent this substitution? What are physicians’ opinions of indication extrapolation?
Future use. Which types of biosimilar manufacturers do physicians trust most? How will physicians adopt biosimilars initially, and will adoption vary by specialty? Will physician uptake be affected by biosimilar price/reimbursement policies? Will physicians use new biologics once biosimilars are available? How will physicians choose between multiple biosimilars of the same reference product?
Markets covered: France, Germany, and the United States.
Primary research: Survey of 90 rheumatologists and 92 gastroenterologists.
Current Treatment Physician Insights Immunology US/EU December 2022
Nuria Carmona, Ph.D., Healthcare Research & Data Analyst, Biosimilars. Previously, she developed her scientific career in the field of cancer immunotherapy, nanotechnology, and molecular oncology. Dr. Carmona also worked as a pharmaceutical consultant at Anima Strategic Consulting. She received her doctorate from the University of Santiago de Compostela in Spain. She also holds an M.Sc. in drug research, development, and control from the University of Barcelona and a B.Sc. in biotechnology from the Autonomous University of Barcelona.
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.